



#116  
mai  
2/26/03

RECEIVED  
TECH CENTER 1600/22  
FEB 11 2003  
PATENT  
Attorney Docstox No P218654  
DHHS Ref. No. E-082-9612

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of:

Chamberlain et al.

Art Unit: 1632

Application No. 09/838,987

Examiner: Wilson, M.

Filed: April 20, 2001

For: HETEROLOGOUS  
BOOSTING IMMUNIZATION

**PRELIMINARY AMENDMENT AND REMARKS**

Commissioner for Patents  
Washington, D.C. 20231

Dear Sir:

Please enter the following amendments and consider the following remarks.

**AMENDMENTS**

**IN THE SPECIFICATION:**

Replace the paragraph beginning at page 1, line 3, with the following:

This application is a continuation of U.S. patent application no. 09/171,086, filed January 22, 1999, now abandoned, which is the national phase of international patent application no. PCT/US97/06632, filed April 21, 1997, now lapsed, which claims the benefit of U.S. provisional patent application no. 60/015,893, filed April 22, 1996, now lapsed.

Replace the paragraph beginning at page 5, line 7, with the following:

**Fig. 1:** Compares the effect of repetitive immunization of the recombinant vaccine vectors on tumor growth and long-term survival in BALB/c mice intravenously challenged with  $10^5$  CT26.CL25 tumor cells to establish pulmonary metastases. The mice were primed with various vectors 3 days post-intravenous challenge and then boosted with same amount and array of vectors 17 days after tumor inoculation. **Fig. 1A** – data of mice primed with no immunogen (None) and later boosted by either no